Comparison of the expression GATA3 in urothelial bladder carcinoma and prostate carcinoma in Hamadan City, West of Iran in 2020
GATA3 in urothelial bladder and prostate carcinoma
Keywords:
Malignancy, Prostatic Neoplasms, GATA3 Transcription Factor, IranAbstract
BACKGROUND: Bladder malignancies are a common type of urological cancer leading to a high rate of mortality and morbidity. Bladder cancer is one of the common cancers in the urinary system, which is the 9th cause
of cancer in the world. The prompt diagnosis and treatment would result in lower burden of the disease. In this study, immunohistochemical (IHC) assessment of GATA3 expression in bladder carcinoma and prostate carcinoma was assessed .
METHODS: In this observational diagnostic study, 90 bladder and 30 prostate cancer biopsies under surgery in Beheshti Hospital in Hamadan City, west of Iran, from February to July 2020, were assessed, and frequency expression of GATA3 in them was evaluated by IHC assay and was compared between bladder carcinoma and prostate carcinoma according to grade. Finally, the results were analyzed by SPSS software.
RESULTS: GATA3 was negative in all prostate carcinoma samples, and it was positive in all urothelial bladder carcinoma samples. The higher GATA3 expression was significantly related to the lower grade of bladder tumor (P = 0.001).
CONCLUSION: Based on the results obtained, it can be concluded that the expression level of GATA3 in bladder carcinoma reaches 100%.
References
Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007; 31(5): 673-80.
Benson Jr RC, Tomera KM, Kelalis PP. Transitional cell carcinoma of the bladder in children and adolescents. J Urol. 1983; 130(1): 54-5.
Gheitasi R, Sadeghi E, Jafari M. Comparison of immunohistochemistry expression of CK7, HMWK and PSA in high-grade prostatic adenocarcinoma and bladder transitional cell carcinoma. Iran J Pathol. 2021; 16(1): 33-9.
Awadalla A, Mortada WI, Abol-Enein H, Shokeir AA. Correlation between blood levels of cadmium and lead and the expression of microRNA-21 in Egyptian bladder cancer patients. Heliyon. 2020; 6(12): e05642.
Potterveld SK, Williamson SR, Al-Obaidy KI, Akgul M, Chan E, Giannico GA, et al. GATA3 expression in Prostatic adenosquamous carcinoma: A potential diagnostic pitfall. Int J Surg Pathol. 2025; 33(1): 85-91.
Bernardo C, Monteiro FL, Direito I, Amado F, Afreixo V, Santos LL, et al. Association between estrogen receptors and GATA3 in Bladder Cancer: A systematic review and meta-analysis of their clinicopathological significance. Front Endocrinol (Lausanne). 2021; 12: 684140.
Yoo D, Min KW, Pyo JS, Kim NY. Diagnostic and prognostic roles of GATA3 immunohistochemistry in urothelial carcinoma. medicina (Kaunas). 2023; 59(8).
Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J Clin Pathol. 2004; 57(7): 687-90.
Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med. 2016; 50(5): 345-54.
Rana C, Babu S, Agarwal H, Singhai A, Kumar M, Singh V, et al. Diagnostic relevance of GATA 3 expression in urinary bladder carcinoma of divergent differentiation and other histological variants. Indian J Surg Oncol. 2021; 12(4): 678-85.
Wang C, Yang S, Jin L, Dai G, Yao Q, Xiang H, et al. Biological and clinical significance of GATA3 detected from TCGA database and FFPE sample in bladder cancer patients. Onco Targets Ther. 2020; 13: 945-58.
Khazaeli Najafabadi M, Mirzaeian E, Memar Montazerin S, Tavangar AR, Tabary M, Tavangar SM. Role of GATA3 in tumor diagnosis: A review. Pathol Res Pract. 2021; 226: 153611.
Wang Y, Wang Y, He H, Xiong Y. Absence of GATA3/FOXA1 co-expression predicts poor prognosis in upper tract urothelial carcinoma. Front Oncol. 2024; 14: 1302864.
Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, et al. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Hum Pathol. 2017; 64: 83-90.
Mohammed KH, Siddiqui MT, Cohen C. GATA3 immunohistochemical expression in invasive urothelial carcinoma. Urol Oncol. 2016; 34(10): 432.e9-.e13.
Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: A useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012; 138(1): 57-64.
Chang A, Amin A, Gabrielson E, Illei P, Roden RB, Sharma R, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012; 36(10): 1472-6.
Gruver AM, Amin MB, Luthringer DJ, Westfall D, Arora K, Farver CF, et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012; 136(11): 1339-46.
Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014; 45(7): 1466-72.
Doamekpor F, Mohamed A, Siddiqui M, Ayman A, Wang T, Ashraf K, et al. GATA3 immunohistochemical expression in urothelial carcinoma. J Clin Oncol. 2016; 34(15): e16135.
Agarwal H, Babu S, Rana C, Kumar M, Singhai A, Shankhwar SN, et al. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019; 62(2): 244-50.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014; 38(1): 13-22.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Chronic Diseases Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
